Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea
Recruiting
Observational Study
Moderate-to-severe Plaque Psoriasis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 19 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 505 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this observational study is to describe the safety and effectiveness of deucravacitinib in participants in Korea that have been diagnosed with moderate-to-severe plaque psoriasis.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adult participants ≥19 years of age
* Diagnosis of moderate-to-severe plaque psoriasis
* Candidate for phototherapy or systemic therapy
* Will begin deucravacitinib according to approved product label
Exclusion Criteria:
* Participants prescribed deucravacitinib for therapeu…
Contacts
BMS Study Connect Contact Center www.BMSStudyConnect.com
855-907-3286
CONTACT
First line of the email MUST contain NCT # and Site #.
CONTACT